What is the prevalence of Rubinstein-Taybi Syndrome?

TL;DR: Rubinstein-Taybi Syndrome (RSTS) is a rare genetic condition with an estimated prevalence ranging from 1 in 100,000 to 1 in 125,000 live births. While RSTS is considered a rare disease, true prevalence is likely higher due to diagnostic challenges and the clinical variability of the syndrome.

How common is Rubinstein-Taybi Syndrome?

Rubinstein-Taybi Syndrome is classified as a rare genetic disorder. Because it is often characterized by specific physical features, such as broad thumbs and halluces (big toes), many cases are identified in early childhood. However, because RSTS manifests with a wide range of clinical severity, mild cases may go undiagnosed or be misidentified as other developmental disorders. Current epidemiological data from sources like Orphanet and the NIH Genetic and Rare Diseases Information Center (GARD) suggest the occurrence is roughly 1 in 100,000 to 125,000 births, though these figures are estimates and not definitive counts of all living individuals.

Are there variations in how Rubinstein-Taybi Syndrome affects different groups?

Rubinstein-Taybi Syndrome affects males and females equally, with no established predilection for either gender. Similarly, there is no evidence of geographic or ethnic variations in the prevalence of Rubinstein-Taybi Syndrome; the condition appears to occur globally across all populations. Because RSTS is primarily caused by de novo (new) mutations in the CREBBP or EP300 genes, it does not typically follow a pattern of inheritance that would cluster in specific ethnic or ancestral groups.

What are the challenges in tracking prevalence data?

Accurate epidemiological tracking of Rubinstein-Taybi Syndrome is hindered by several factors common to rare diseases. The primary challenges include:

• Diagnostic overshadowing: The cognitive and physical traits of Rubinstein-Taybi Syndrome can sometimes be attributed to other genetic syndromes, leading to misdiagnosis.


• Clinical spectrum: Individuals with mild mutations or mosaicism may not present with the "classic" physical markers, leading to under-ascertainment in clinical registries.


• Data fragmentation: Because RSTS is rare, data is often collected in small, localized cohorts rather than large, global population-based studies.

How does the DiseaseMaps community reflect the prevalence of Rubinstein-Taybi Syndrome?

While clinical literature provides statistical estimates, real-world data offers a different perspective on the lived experience of those with the condition. The DiseaseMaps.org community currently includes 232 people with Rubinstein-Taybi Syndrome who have shared their experiences. This community data serves as a vital bridge between theoretical prevalence numbers and the actual population of families navigating life with Rubinstein-Taybi Syndrome, highlighting the importance of patient-led registries in rare disease research.

Is Rubinstein-Taybi Syndrome a pediatric or adult condition?

Rubinstein-Taybi Syndrome is a lifelong condition. While diagnosis often occurs in the pediatric period due to the prominence of physical features at birth or during infancy, individuals with Rubinstein-Taybi Syndrome live into adulthood. As the medical community improves care for patients with Rubinstein-Taybi Syndrome, the focus is increasingly shifting toward the unique medical, psychological, and social needs of adults living with the syndrome.

Next steps

• Consult a clinical geneticist to discuss genetic testing options if you suspect a diagnosis of Rubinstein-Taybi Syndrome.


• Connect with the DiseaseMaps.org community to share experiences and find resources for daily management.


• Review the latest clinical trial information via the NIH GARD or ClinicalTrials.gov to stay informed about ongoing research.


• Work with a multidisciplinary care team, including pediatricians, neurologists, and therapists, to manage the multisystem needs associated with the condition.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Rubinstein-Taybi Syndrome (ORPHA:791).


• NIH Genetic and Rare Diseases Information Center (GARD): Rubinstein-Taybi Syndrome.


• OMIM (Online Mendelian Inheritance in Man): Entry #180849 (RSTS1) and #613684 (RSTS2).


• Rubinstein-Taybi Syndrome Support Groups and Foundation literature.